ABCL
NASDAQ · Life Sciences Tools & Services
Abcellera Biologics Inc
$11.88
+0.75 (+6.74%)
ABCL News4 articles
AbCellera Surges 34% as Menopause Drug Hits Phase 2 Goals
AbCellera (ABCL) surged 34% after its menopause drug ABCL635 met Phase 2 efficacy endpoints, reducing hot flash frequency and severity with no dropouts.
AbCellera Shares Soar 37% on Promising Menopause Drug Data
AbCellera (ABCL) surged 37.5% after its menopause drug ABCL635 met all primary and secondary endpoints in a Phase 2 trial, reducing hot flash frequency by 83%.
AbCellera Shares Jump 9.7% Ahead of Key Phase 2 Data Release
AbCellera (ABCL) rose 9.7% after hours as investors await Phase 2 data for ABCL635, set to release Monday. The surge adds ~$205M to market cap.
Recursion Pharmaceuticals Hits New Low Amid Revenue Drop and FDA Watch
Recursion Pharmaceuticals shares fell to a 52-week low Tuesday after Q1 revenue dropped 56% year-over-year. The AI-driven biotech firm awaits FDA feedback on key trials.